Combination fixed-dose β agonist and steroid inhaler as required for adults or children with mild asthma: a Cochrane systematic review.

Authors: Crossingham I; Turner S; Ramakrishnan S; et al.
Source: BMJ evidence-based medicine [BMJ Evid Based Med] 2022 Jun; Vol. 27 (3), pp. 178-184. Date of Electronic Publication: 2021 Jul 19.
Abstract:  In people with mild asthma poor adherence to regular therapy is common and increases the risk of exacerbations, morbidity and mortality. The use of fixed dose combination inhalers containing an inhaled corticosteroid (ICS) and a fast-acting β 2 -agonist (FABA) is established in moderate asthma, but they may also have potential utility in mild asthma.
Objectives: To evaluate the efficacy and safety of single combined FABA/ICS inhaler only used as needed in people with mild asthma.

Full text available here